Eledon Pharmaceuticals (ELDN) announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America (DNPUF) on July 1, 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ELDN:
- Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
- Eledon announce publication fo study evaluating tegoprubart
- Eledon Pharmaceuticals begins dosing in Phase 2 trial of tegoprubart
- Eledon announces dosing of 10th patient in Phase 1b trial of tegoprubart
- Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results